MarketPeel
Insider Trading Intelligence
Pricing
…
BG

Brian Goff

AGIO
CHIEF EXECUTIVE OFFICER · AGIOS PHARMACEUTICALS, INC. · CIK 0001546216
FILING MIX · LIFETIME48%/52%
BUYS
36
SELLS
39
TOTAL VALUE
$5.41M
COMPANIES
2
ACTIVE SINCE
Aug 2022
HOLDINGS NOW
52,300
AVG SELL PX
$32.37
TRADE KIND
SHOWING 75 / 75
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
19 backtested trades · 8 horizons · 26 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Brian Goff, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d19+57.89%-1.14%+0.34%-1.48%-1.11%—
14d19+57.89%+0.27%+1.14%-0.88%+0.74%—
30d19+42.11%+2.49%+1.72%+0.77%-0.01%—
60d19+57.89%+2.73%+2.67%+2.32%-3.75%—
90d19+26.32%+8.38%+4.30%+5.53%+4.38%—
180d19(5 pending)+42.86%+17.28%+11.34%+5.94%+3.03%—
1y19(8 pending)+36.36%+15.52%+20.04%-4.52%-15.87%—
2y19(13 pending)+33.33%+9.16%+43.14%-33.97%-27.85%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AGIO · 39,000 shares · as of Jun 18, 2026
0140,271280,542420,812561,0832023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 36 buys / 39 sellsCOVERAGE · 16 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
39,000——39,000Jun 18, 2026Jun 23, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
39,000——39,000Jun 18, 2026Jun 23, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,300——13,300Jun 9, 2026Jun 10, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,200——32,609Jun 9, 2026Jun 10, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,528——0Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,596$34.71$228.9K184,508Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
13,500——40,500Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
13,500——191,104Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,528——190,076Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,472$34.71$432.9K177,604Apr 2, 2026Apr 6, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
8,500——0Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
8,267$28.96$239.4K157,466Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,870$28.96$112.1K147,733Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
13,000——26,000Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
13,000——170,466Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
18,000——18,000Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
8,500——151,603Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
18,000——165,733Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,918$28.96$171.4K164,548Mar 2, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
174,000——174,000Mar 1, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
48,000——48,000Mar 1, 2026Mar 3, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,473$27.09$337.9K136,583Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
12,750——0Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,528——25,528Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
12,750——149,333Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,528——149,056Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,230$27.09$168.8K143,103Dec 30, 2025Jan 2, 2026 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
22,691——134,613Aug 8, 2025Aug 12, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
22,691——0Aug 8, 2025Aug 12, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,085$36.67$406.5K123,528Aug 8, 2025Aug 12, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,527——51,056Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,471$33.54$418.3K105,401Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
12,750——118,151Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
12,750——12,750Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,229$33.54$208.9K111,922Jun 24, 2025Jun 26, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,527——117,872Jun 24, 2025Jun 26, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,450——11,450Jun 11, 2025Jun 13, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,000——23,409Jun 11, 2025Jun 13, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
8,794$35.54$312.5K92,345Mar 3, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,153$35.54$147.6K83,139Mar 3, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
39,000——39,000Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
18,000——101,139Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
8,500——87,292Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
142,500——142,500Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
18,000——36,000Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
8,500——8,500Mar 1, 2025Mar 4, 2025 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
22,691——22,691Aug 8, 2024Aug 12, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,091$42.75$474.1K78,792Aug 8, 2024Aug 12, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
22,691——89,883Aug 8, 2024Aug 12, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,409——15,409Jun 13, 2024Jun 17, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
22,297——22,297Jun 13, 2024Jun 17, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,115$48.84$591.7K67,192Jun 5, 2024Jun 7, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,527——79,307Jun 5, 2024Jun 7, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,527——76,583Jun 5, 2024Jun 7, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,156$32.57$135.4K53,780Mar 5, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
8,500——17,000Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
8,500——57,936Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
195,500——195,500Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
54,000——54,000Mar 1, 2024Mar 5, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
7,635$21.64$165.2K49,436Jan 24, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
17,018——102,110Jan 20, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
17,018——57,071Jan 20, 2024Jan 24, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,066$22.99$277.4K40,053Jan 9, 2024Jan 9, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,527——119,128Jan 5, 2024Jan 9, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,527——52,119Jan 5, 2024Jan 9, 2024 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,178$25.48$259.3K26,592Aug 8, 2023Aug 10, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
22,691——45,382Aug 8, 2023Aug 10, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
22,691——36,770Aug 8, 2023Aug 10, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,449$28.36$324.7K14,079Jun 30, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
25,528——25,528Jun 28, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
25,528——144,655Jun 28, 2023Jun 30, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
94,500——94,500Mar 1, 2023Mar 3, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,500——25,500Mar 1, 2023Mar 3, 2023 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
68,073——68,073Aug 8, 2022Aug 9, 2022 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
561,083——561,083Aug 8, 2022Aug 9, 2022 ↗View →
Other insiders · AGIO
Loading peer insiders…
About this filer
CIK 0001546216
ROLE
Chief Executive Officer
PRIMARY
AGIO
COMPANIES
2
ACTIVE SINCE
Aug 2022
MARKETPEEL · /INSIDER/0001546216DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback